BACKGROUND: Synucleinopathies, including Parkinson's disease (PD), are characterized by α-synuclein (αS) cytoplasmic inclusions. αS-dependent vesicle-trafficking defects are important in PD pathogenesis, but their mechanisms are not well understood. Protein palmitoylation, post-translational addition of the fatty acid palmitate to cysteines, promotes trafficking by anchoring specific proteins to the vesicle membrane. αS itself cannot be palmitoylated as it lacks cysteines, but it binds to membranes, where palmitoylation occurs, via an amphipathic helix. We hypothesized that abnormal αS membrane-binding impairs trafficking by disrupting palmitoylation. Accordingly, we investigated the therapeutic potential of increasing cellular palmitoylation. OBJECTIVES: We asked whether upregulating palmitoylation by inhibiting the depalmitoylase acyl-protein-thioesterase-1 (APT1) ameliorates pathologic αS-mediated cellular phenotypes and sought to identify the mechanism. METHODS: Using human neuroblastoma cells, rat neurons, and iPSC-derived PD patient neurons, we examined the effects of pharmacologic and genetic downregulation of APT1 on αS-associated phenotypes. RESULTS: APT1 inhibition or knockdown decreased αS cytoplasmic inclusions, reduced αS serine-129 phosphorylation (a PD neuropathological marker), and protected against αS-dependent neurotoxicity. We identified the APT1 substrate microtubule-associated-protein-6 (MAP6), which binds to vesicles in a palmitoylation-dependent manner, as a key mediator of these effects. Mechanistically, we found that pathologic αS accelerated palmitate turnover on MAP6, suggesting that APT1 inhibition corrects a pathological αS-dependent palmitoylation deficit. We confirmed the disease relevance of this mechanism by demonstrating decreased MAP6 palmitoylation in neurons from αS gene triplication patients. CONCLUSIONS: Our findings demonstrate a novel link between the fundamental process of palmitoylation and αS pathophysiology. Upregulating palmitoylation represents an unexplored therapeutic strategy for synucleinopathies.
BACKGROUND: Synucleinopathies, including Parkinson's disease (PD), are characterized by α-synuclein (αS) cytoplasmic inclusions. αS-dependent vesicle-trafficking defects are important in PD pathogenesis, but their mechanisms are not well understood. Protein palmitoylation, post-translational addition of the fatty acid palmitate to cysteines, promotes trafficking by anchoring specific proteins to the vesicle membrane. αS itself cannot be palmitoylated as it lacks cysteines, but it binds to membranes, where palmitoylation occurs, via an amphipathic helix. We hypothesized that abnormal αS membrane-binding impairs trafficking by disrupting palmitoylation. Accordingly, we investigated the therapeutic potential of increasing cellular palmitoylation. OBJECTIVES: We asked whether upregulating palmitoylation by inhibiting the depalmitoylase acyl-protein-thioesterase-1 (APT1) ameliorates pathologic αS-mediated cellular phenotypes and sought to identify the mechanism. METHODS: Using human neuroblastoma cells, rat neurons, and iPSC-derived PD patient neurons, we examined the effects of pharmacologic and genetic downregulation of APT1 on αS-associated phenotypes. RESULTS: APT1 inhibition or knockdown decreased αS cytoplasmic inclusions, reduced αS serine-129 phosphorylation (a PD neuropathological marker), and protected against αS-dependent neurotoxicity. We identified the APT1 substrate microtubule-associated-protein-6 (MAP6), which binds to vesicles in a palmitoylation-dependent manner, as a key mediator of these effects. Mechanistically, we found that pathologic αS accelerated palmitate turnover on MAP6, suggesting that APT1 inhibition corrects a pathological αS-dependent palmitoylation deficit. We confirmed the disease relevance of this mechanism by demonstrating decreased MAP6 palmitoylation in neurons from αS gene triplication patients. CONCLUSIONS: Our findings demonstrate a novel link between the fundamental process of palmitoylation and αS pathophysiology. Upregulating palmitoylation represents an unexplored therapeutic strategy for synucleinopathies.
Authors: Andreas M Ernst; Saad A Syed; Omar Zaki; Francesca Bottanelli; Hong Zheng; Moritz Hacke; Zhiqun Xi; Felix Rivera-Molina; Morven Graham; Aleksander A Rebane; Patrik Björkholm; David Baddeley; Derek Toomre; Frederic Pincet; James E Rothman Journal: Dev Cell Date: 2018-11-19 Impact factor: 12.270
Authors: Juan J Zarranz; Javier Alegre; Juan C Gómez-Esteban; Elena Lezcano; Raquel Ros; Israel Ampuero; Lídice Vidal; Janet Hoenicka; Olga Rodriguez; Begoña Atarés; Verónica Llorens; Estrella Gomez Tortosa; Teodoro del Ser; David G Muñoz; Justo G de Yebenes Journal: Ann Neurol Date: 2004-02 Impact factor: 10.422
Authors: Nikos S Hatzakis; Vikram K Bhatia; Jannik Larsen; Kenneth L Madsen; Pierre-Yves Bolinger; Andreas H Kunding; John Castillo; Ulrik Gether; Per Hedegård; Dimitrios Stamou Journal: Nat Chem Biol Date: 2009-09-13 Impact factor: 15.040
Authors: Silke Nuber; Molly Rajsombath; Georgia Minakaki; Jürgen Winkler; Christian P Müller; Maria Ericsson; Barbara Caldarone; Ulf Dettmer; Dennis J Selkoe Journal: Neuron Date: 2018-10-10 Impact factor: 17.173
Authors: Chee Yeun Chung; Vikram Khurana; Pavan K Auluck; Daniel F Tardiff; Joseph R Mazzulli; Frank Soldner; Valeriya Baru; Yali Lou; Yelena Freyzon; Sukhee Cho; Alison E Mungenast; Julien Muffat; Maisam Mitalipova; Michael D Pluth; Nathan T Jui; Birgitt Schüle; Stephen J Lippard; Li-Huei Tsai; Dimitri Krainc; Stephen L Buchwald; Rudolf Jaenisch; Susan Lindquist Journal: Science Date: 2013-10-24 Impact factor: 47.728
Authors: Daniel F Tardiff; Matthew Lucas; Iwona Wrona; Belle Chang; Chee Yeun Chung; Bertrand Le Bourdonnec; Kenneth J Rhodes; Robert H Scannevin Journal: Mol Neurobiol Date: 2022-01-20 Impact factor: 5.682